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Abstract
Purpose: To report the retrospective analysis of patients with locally advanced rectal cancer treated with
neodjuvant radiochemotherapy.
Methods and Materials: From January 1994 to December 2003, 101 patients with fixed (25%) or semi-
fixed (75%) rectal adenocarcinoma were treated by preoperative radiotherapy with a dose of 45Gy at the
whole pelvis and 50.4Gy at primary tumor, concomitant to four weekly chemotherapies with 5-
Fluorouracil (425 mg/m2) and Leucovorin (20 mg/m2). In 71 patients (70.3%) the primary tumor was
located up to 6 cm from the anal verge and in 30 (29.7%) from 6.5 cm to 10 cm. Age, gender, tumor
fixation, tumor distance from the anal verge, clinical response, surgical technique, and postoperative TNM
stage were the prognostic factors analyzed for overall survival (OS), disease-free survival (DFS), and local
control (LC) at five years.
Results: Median follow-up time was 38 months (range, 2–141). Complete response was observed in eight
patients (7.9%), partial in 54 (53.4%) and absence in 39 (38.7%). OS, DFS and LC were 52.6%, 53.8%, and
75.9%, respectively. Distant metastasis occurred in 40 (39.6%) patients, local recurrence in 20 (19.8%) and
both in 16 (15.8%). Patients with fixed tumors had lower OS (17% Vs 65.6%; p < 0.001), DFS (31.2% Vs
60.9%; p = 0.005), and LC (58% Vs 82%; p = 0.004). Patients with tumors more than 6 cm above the anal
verge had better LC (93% Vs 69%; p = 0.04). The postoperative TNM stage was a significant factor for DFS
(I:64.1%, II:69.6%, III:35.2%, IV:11.1%; p < 0.001) and for LC (I:75.7%, II: 92.9%, III:54.1%, IV:100%; p =
0.005). Patients with positive lymph nodes had worse OS (37.9% Vs 70.4%, p = 0.006), DFS (32% Vs 72.7%,
p < 0.001) and LC (56.2% Vs 93.4%; p < 0.001).
Conclusion: This study suggests that the neoadjuvant treatment employed was effective for local control.
Fixation of the lesion and lymph nodes metastasis were the main adverse prognostic factors. Distant
failures were frequent, supporting the need of new drugs for adjuvant chemotherapy.
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Introduction
The employment of preoperative radiotherapy (RT) com-
bined or not with chemotherapy (CT) has been used in
the treatment of rectal cancer for the past two decades and
its employ gradually increased as adjuvant therapy, espe-
cially in T3/T4 and/or N1/N2 tumors [1,2]. The strategy of
performing preoperative instead of postoperative treat-
ment, has the proven advantages of lower acute toxicity
[3-6], lower total dose of radiation needed [4] and even-
tual tumor regression and downstaging to enable curative
resection and even sphincter preservation [7-17]. Further-
more, some authors showed better local control with pre-
operative RT when compared to surgery alone [7-
10,18,19]. Upon comparison with the postoperative radi-
ochemotherapy approach for adjuvant treatment, data
suggest that local control was better using preoperative
radiochemotherapy [20]. In preoperative therapy, the
association of CT increases pathologic downstaging when
compared to radiation alone [21]. Theoretical advantages
of the preoperative strategy include increased radiosensi-
tivity due to more oxygenated cells and decrease of tumor
seeding during surgery [22]. For patients with fixed or
tethered tumors to adjacent structures, the goal of preop-
erative RT, preferably combined with CT, is to achieve
maximal tumor regression to facilitate resection.
This study reports results on patients with fixed and semi-
fixed adenocarcinoma of the rectum treated with preoper-
ative radiochemotherapy, as well as the analysis of some
prognostic factors that could have influenced the out-
come.
Methods and materials
Patient and tumor characteristics
From January 1994 to December 2003, 101 patients with
locally advanced rectal cancer, characterized by fixed or
semi-fixed tumor, were treated with preoperative RT con-
comitant to CT. All patients had biopsy proven adenocar-
cinoma of the rectum and they were staged through
physical exam, including digital rectal examination of the
primary lesion by the same team of surgeons, chest radio-
graph, computerized tomography of the abdomen and
pelvis, blood chemistries, HIV test and colonoscopy.
Endorectal ultrasound was not used for staging these
patients. A semi-fixed tumor was that with preserved
mobility in at least one direction at digital rectal examina-
tion. The tumor distance from the anal verge was meas-
ured by colonoscopy. Table 1 summarizes the patients
and tumor characteristics.
Radiotherapy
All patients received whole pelvic radiation with dose of
45Gy in 25 daily fractions of 1.8Gy, over five weeks, by
four fields, followed by a boost to the primary tumor of
up to 50.4Gy, with at least 2 cm margins, by three fields
(one posterior and two laterals). The upper limit of all the
pelvic fields was at the L5-S1 level and the lower one was
4 to 5 cm below the tumor. The lateral fields covered the
sacrum and coccyx posteriorly and the femoral head ante-
riorly. The photon energy used was given by a 4 or 6 MV
linear accelerator. The dose was prescribed to the 95%
isodose line. All fields were treated daily and weighting
was 2:1 for the posterior – anterior and laterals incidences,
respectively, for four fields whole pelvis, and 2:1:1 for the
posterior, right lateral, and left lateral portals, respectively,
for three fields boost. Wedges of different degrees were
employed over the lateral fields to homogenize the isod-
ose distribution. The isodoses distribution was designed
by 2D treatment planning system.
Chemotherapy
The CT was performed with two hours bolus infusion of
5-Fluorouracil (5-FU) and leucovorin (LV), once a week,
with a median of four cycles (range: 2-6). The median
dose of 5-FU per cycle was of 425 mg/m2 (range: 88 – 800
mg/m2) and all patients treated with CT received 20 mg/
m2 of LV. During the radiochemotherapy course, acute
toxicity was evaluated. If nausea, vomiting, diarrhea,
mucositis or leucopenia were not controlled with medica-
tion, the treatment was temporarily interrupted. The deci-
sion of performing this weekly CT schedule instead of
during the first and last week of RT course had the objec-
tive of maximize the radiation effect.
Adjuvant CT was employed in all patients with postoper-
ative lymph-nodes metastasis and in those who presented
unresectable primary tumor or intrabdominal disease dis-
semination during surgery. This CT was based on 5-FU
and LV.
Preoperative evaluation and surgery
Four weeks after the radiochemotherapy course, all
patients were evaluated and restaged by means of physical
Table 1: Patients and tumor characteristics.
Patient number 101
Period Jan/1994 – Dec/2003
Age (year)
Median 62
Range (25 – 84)
Gender
Male 52 (51.5%)
Female 49 (48.5%)
Tumor distance from the anal verge
0–6 cm 71 (70.3%)
6.5–10 cm 30 (29.7%)
Tumor mobility
Fixed 25 (24.7%)
Semi-fixed 76 (75.3%)Radiation Oncology 2006, 1:5 http://www.ro-journal.com/content/1/1/5
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examination, computerized tomography of the abdomen
and pelvis, chest x-ray, blood chemistries, and colonos-
copy. If at colonoscopy no tumor was visualized, patients
were considered as having a complete clinical response,
partial response was considered if tumor regressed more
than 50% of the initial volume, and no response if the
tumor did not regress more than 50%. Surgery was
planned to take place four to six weeks after the radioche-
motherapy course. The surgical technique was decided by
the surgeon's team, based on tumor location, clinical
response, and intraoperative findings. All patients treated
with surgery underwent total mesorectal excision by
means of anterior resection, abdominoperineal resection
or pelvic exenteration. Postoperative stage was classified
by the American Joint Committee on Cancer (AJCC) TNM
staging system [23], based on pathologic findings.
Patients with complete pathologic response were consid-
ered as stage 0 (T0N0M0).
Follow-up
Follow-up was performed at every 3 months in the first
two years following completion of surgery, and at a mini-
mum of 6 months thereafter. At each follow-up all
patients underwent clinical examination and also a rectos-
igmoidoscopy in those treated with sphincter saving sur-
gery. Chest radiograph and abdominopelvic
computerized tomography were done every 6 months in
the first 3 years and every 12 months thereafter or when
clinically required.
Statistical analysis
All statistical analyses were performed with a software
program Statistics/Data analysis (STATA Corporation,
Houston: University of Texas; 2000). Overall survival
(OS), disease free survival (DFS), and local control (LC)
were calculated according to the actuarial method of Kap-
lan and Meier [24]. The calculation of OS, DFS and LC was
performed from the date of diagnosis to the date of the
event. Survival was measured from the date of diagnosis
to death or last follow-up. Patients who died of diseases
unrelated to cancer were censored. The prognostic factors
analyzed were: patient's age, gender, pretreatment tumor
status (fixation), tumor distance from the anal verge, clin-
ical response to the neoadjuvant treatment by colonos-
copy, surgical technique employed, and postoperative
TNM stage. The log-rank test was used to compare the
actuarial probabilities curves for OS, DFS and LC. Relative
risk of death was determined by Cox regression analysis
[25]. Comparison of categorical variables was performed
using the chi-square (χ2) test. Values of p lesser than 0.05
or 95% were considered as having a statistical signifi-
cance. Last revision of this analysis was carried out in July
2005.
Results
Neadjuvant treatment
Of the 101 patients treated, 7 (6.9%) did not complete the
prescribed dose of preoperative RT because of persistent
neutropenia and/or diarrhea. Of these, two died due to
septicemia and the other five underwent surgery before
the end of radiochemotherapy. Doses administered to
these patients ranged from 14.4Gy to 39.6Gy at the whole
pelvis. During the RT course, 88 (87.1%) patients received
concomitant weekly CT. Thirteen patients (12.9%) did
not receive CT because of inadequate clinical conditions.
Temporary interruption of both treatment (RT and CT)
with a median duration of one week, due to leucopenia,
diarrhea or mucositis not controlled with medication, was
necessary in 22 (21.8%) patients (grade 3 toxicity). The
rate of treatment response, evaluated four weeks after the
end of RT, was considered complete in eight (7.9%)
patients, partial in 54 (53.4%), and null in 39 (38.6%).
None of the patients developed tumor progression during
or up to four weeks after RT.
Surgery
Surgery was performed four to six weeks after RT in 89
patients (88%). Of these, 83 (82%) had the primary
tumor removed and 6 (5.9%) underwent only colostomy
because of unresectable tumor and/or disease dissemina-
tion detected during laparotomy. All patients treated by
surgery underwent total mesorectal excision and accord-
ing to the surgical technique employed for tumor
removal, 38 (37.6%) were by anterior resection (AR), 36
(35.6%) were by abdominoperineal resection (APR), and
9 (9%) were by pelvic exenteration. All 83 patients with
surgical removal of the tumor had negative resection mar-
gins, including the circumferential one.
Twelve (11.8%) patients were not submitted to surgery
because two died during the neoadjuvant treatment, five
presented distant metastasis at restaging procedures and
five refused surgery because they achieved complete clini-
cal response after radiochemotherapy course. These last
patients have been followed up every three months. One
developed distant metastasis after 14 months of follow-up
and died 17 months after diagnosis with no local failure.
This patient was initially staged as T4 because of vaginal
invasion. The other four patients are alive with no evi-
dence of disease with median follow-up of 72 months
(range: 48 – 96). These patients had the primary tumor
located from 2 to 6 cm from the anal verge and they were
considered candidates to APR by the surgeon prior to neo-
adjuvant treatment.
Sphincter preservation
Among 71 patients with distal rectal cancer (tumor up to
6 cm from the anal verge) and initially considered candi-
dates to APR, 14 (19.7%) underwent sphincter-sparingRadiation Oncology 2006, 1:5 http://www.ro-journal.com/content/1/1/5
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low AR and coloanal anastomosis. Of these, one patient
had tumor located 2 cm from the anal verge, one had it
located 3 cm away and the remaining at a 4 to 5 cm dis-
tance. In this group, the 5-year local control probability
was of 58.8%. The patient with the tumor 2 cm from the
anal verge was postoperative stage T3N2M0 and devel-
oped both local and distant failures. Adding these patients
with the five with distal rectal cancer who refused surgery
and did not develop local failure, the sphincter preserva-
tion rate among patients with initial indication of APR
was of 26.8% (19/71).
Postoperative staging and surgical findings
The postoperative TNM staging of the 83 patients with pri-
mary tumor removed by surgery, according to AJCC is
shown in Table 2. The primary tumor was not removed in
six patients because it was unresectable in three, two had
intrabdominal disease dissemination and one presented
both. Among patients with the primary tumor removed
by surgery, 33 (39.7%) had lymph-node metastasis at
pathology report (N1/N2) and their T stage distribution
was: T0:2 (2.4%); T1:2 (2.4%); T2:26 (31.3%); T3:42
(41.6%); and T4:11 (13.2%). Of the 25 patients with ini-
tially fixed tumors, 16 (64%) underwent tumor resection
by AR (5 patients), APR (6 patients) or pelvic exenteration
(5 patients).
Patient's follow-up and patterns of failure
Median follow- up time was 38 months (range, 2 – 141).
At the time of this analysis, 46 patients (45.5%) were alive
with no evidence of disease, 5 (4.9%) were alive with evi-
dence of disease, 42 (41.6%) died due to the rectal cancer,
4 (4%) died of second primary tumor, and 4 (4%) died
due of diseases unrelated to cancer. According to the pat-
tern of failure, 24 (23.8%) patients developed only distant
metastasis, 4 (4%) had only local recurrence, and 16
(15.8%) developed both. Two patients who developed
only local failure were rescued by a second surgery. Eight
(7.9%) patients developed second primary tumor. Of
these, two had lung cancer and died; one had low grade
non Hodgkin's lymphoma and is alive with no evidence
of disease; one had bladder cancer and died of causes
unrelated to cancer; one had kidney cancer and died of
rectal cancer; one developed prostate cancer and is alive
with no evidence of disease; one developed acute lym-
phoblastic leukemia and died of it, and one died due to a
glioblastoma multiform of the brain.
Actuarial results and prognostic factors
Using the Kaplan-Meier actuarial method, probabilities of
OS, DFS, and LC at five years for all patients were 52.6%
(Figure 1), 53.8%, and 75.9%, respectively. For OS, age,
gender, tumor location, postoperative TNM stage, and
clinical response were not statistically significant factors.
Patients with fixed tumor had worse 5-year OS (17% Vs
65.7%; p < 0.001) (Figure 2) as well as those with positive
postoperative lymph nodes (37.9% Vs 70.4%; p = 0.006)
(Figure 3).
For DFS, age, gender, tumor location, surgical technique,
and clinical response were not statistically significant fac-
tors. Patients with fixed tumors had worse DFS, as well as
those with positive postoperative lymph-nodes (Table 3),
and those with postoperative stages III and IV (Table 3
and figure 4).
The probability of LC at five years was not influenced by
age, gender, clinical response, surgical technique, and
postoperative T stage. Better 5-year LC was observed in
patients with semi-fixed tumor (Table 3) and in those
with tumor located above 6 cm from the anal verge (Table
3 and figure 5). Patients with postoperative stage III dis-
ease had lower 5-year local control, as well those with
postoperative positive lymph-nodes (Table 3).
Estimated relative risk of death, calculated by Cox regres-
sion analysis, was higher among patients with fixed
tumors and with postoperative positive lymph-nodes
(Table 4).
Discussion
For locally advanced rectal cancer, the employment of pre-
operative radiotherapy, preferably combined with chemo-
therapy, is an interesting treatment strategy due to the
possibility of tumor downstaging, which leads to an
enhanced resectability rate [11,12,14-17]. Other advan-
tages of this treatment strategy, already reported in litera-
ture, include sterilization of the tumor bed, easier
displacement of the small bowel and a lower total dose of
radiation needed [5,26-29].
Table 2: Postoperative TNM staging distribution by AJCC
Stage n (%)
02  ( 2 . 4 % )
T0N0M0 2 (2.4%)
I2 0  ( 2 4 . 1 % )
T1N0M0 2 (2.4%)
T2N0M0 18 (21.7%)
II 26 (31.3%)
T3N0M0 22 (26.5%)
T4N0M0 4 (4.8%)
III 30 (36.1%)
T2N1-2M0 7 (8.4%)
T3N1-2M0 16 (19.3%)
T4N1-2M0 7 (8.4%)
IV 5 (6%)
T2N1M1 1 (1.2%)
T3N0M1 2 (2.4%)
T3N1M1 2 (2.4%)
Abbreviation: AJCC = American Joint Committee on Cancer.Radiation Oncology 2006, 1:5 http://www.ro-journal.com/content/1/1/5
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In this study, all patients had locally advanced primary
tumors and were classified as fixed or semi-fixed ones.
After the radiochemotherapy course, 83 (82%) patients
had the tumor resected with negative margins. The down-
staging achieved was not precisely determined because the
endorectal ultrasound was not used for staging, but 30
(29.7%) patients presented postoperative T0 – T2 tumors
(Table 2). Furthermore, among 25 patients with fixed
tumor and initially supposed to be unresectable, 16
(64%) was resected with negative margins. The actuarial
5-year local control rate of 75.9% was reasonable, consid-
ering the initial extension of the primary tumor. This
result is consistent with other series from literature that
report similar local control rates in patients with locally
advanced tumors treated with preoperative radiotherapy
with or without chemotherapy [12,15,16,30-37]. In our
series, distant metastasis was the predominant pattern of
failure. This implies the need of new drugs for adjuvant
treatment for these patients.
For resectable rectal tumors, preoperative RT seems to
achieve better local control than the postoperative RT, as
reported by the prospective and randomized German trial
CAO/ARO/AIO 94 [20] and by two metanalyses [38,39].
At our Institution, we still do not use preoperative RT for
resectable tumors. This group of patients is at first treated
with surgical resection and the indication of adjuvant
treatment is determined by the pathology report. In the
future, we will probably design a prospective and rand-
omized phase III trial similar to the German one to com-
pare preoperative with postoperative radiochemotherapy
in the management of rectal cancer, even for resectable
tumors.
Endorectal sonography can be useful for staging primary
rectal tumors before surgery or preoperative radiochemo-
therapy, mainly for resectable tumors, which will help to
elect the surgical technique. Although the accuracy of this
Table 3: Disease-free survival (DFS) and local control (LC) probability at five years by prognostic factors.
Prognostic factor Category DFS P LC p
Tumor fixation Semi-fixed 60.1% 0.005 81.9% 0.004
Fixed 31.2% 58.2%
Tumor distance from 
the anal verge
≤ 6 cm 48.1% 0.19 69.3% 0.043
> 6 cm 67.1% 92.6%
Postoperative stage I 64.1% <0.001 75.7% 0.005
II 69.6% 92.9%
III 35.2% 54.1%
IV 11.1% 100%
Postoperative N stage N0 72.7% <0.001 93.4% <0.001
N1/N2 32.0% 56.3%
Actuarial overall survival probability for all patients Figure 1
Actuarial overall survival probability for all patients.
0 30 60 90 120 150
0.00
0.25
0.50
0.75
1.00
Months
Actuarial overall survival probability by tumor fixation Figure 2
Actuarial overall survival probability by tumor fixation.
0 30 60 90 120 150
P<0.0001
Fixed
Semi-fixed
1.00
0.75
0.50
0.25
0.00
MonthsRadiation Oncology 2006, 1:5 http://www.ro-journal.com/content/1/1/5
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exam is of approximately 70% [40,41], two recent studies
with preoperative radiotherapy showed that it is insuffi-
cient to stage lymph-node involvement [42,43]. As all
patients in our study at digital rectal examination had
fixed or semi-fixed tumors, we did not use this exam dur-
ing the staging procedures. Furthermore, postoperative
pathology staging has been demonstrated to be a more
accurate prognostic factor than the ultrasound staging
[42-44].
Our Institution had already begun a prospective trial to
test the possibility of avoiding surgery in patients with dis-
tal rectal adenocarcinoma who had presented pathologic
complete response after 4 weeks of 50.4Gy of radiation at
the whole pelvis, concomitant to CT with 5-FU (425 mg/
m2/day) and LV (20 mg/m2/day) during the first 3 days
and the last 3 days of RT [45]. These patients had received
a radiotherapy boost at the primary tumor site with a
20Gy dose to replace surgical resection. Of 52 patients
enrolled in this study, 10 (19.2%) achieved pathologic
complete response and underwent radiation boost with
no surgery. Of these, eight (80%) developed local recur-
rence within 3.7 to 8.8 months [46]. These findings have
influenced our surgical team not to try sphincter preserva-
tion in distal rectal cancer, even after complete response to
the radiochemotherapy course. Although sphincter pres-
ervation was not the main goal of our study, 19.7%
patients initially candidate to APR underwent sphincter-
sparing low AR and coloanal anastomosis. The 5-year
local control in this group of patients was of 58.8%, sug-
gesting that this strategy can compromise the local con-
trol.
In the management of distal rectal cancer, sphincter-spar-
ing surgery is nowadays the main subject of controversy.
One of the most important controversies is whether the
degree of downstaging warrants this type of surgery [1].
Results of the German (CAO/ARO/AIO 94) randomized
trial of preoperative versus postoperative combined radi-
ochemotherapy suggest that this assessment is accurate
[20]. A preliminary report of the NSABP R-03 trial
revealed that the proportion of patients who underwent
sphincter-sparing surgery and were disease free was higher
in the preoperative than the postoperative arm (44% Vs
34%) and that the rate of sphincter preservation among
distal rectal cancer patients was 23% [47], similar to our
results. Unfortunately, this trial was closed early because
of small patient accrual. Other series from literature report
the rate of sphincter preservation among patients with ini-
tially resectable distal rectal cancer ranging from 30% to
70%, with local failure of approximately 10% [15,16,47-
56]. At our Institution, we believe that more prospective
trials with longer follow-up are required to authorize a
change of philosophy about margin resection.
Curiously, five patients in our study refused surgical resec-
tion after complete clinical response. Of these, four are
still alive with no evidence of disease with a relative long
follow-up (48 – 96 months). Probably, in this group of
patients, tumors had some molecular markers which
afforded them better response to preoperative therapy.
Some authors have already studied selected molecular
markers such as c-K-ras, thymidylate synthase, p53,
p27Kkip1, DCC, EGFR, TP53, Ki-67, and apoptosis to
identify this group of patients [57-64]. However, these
studies are still limited and in the future, it will be imper-
ative to identify some groups of patients by means of tis-
sue collections to better choose the most appropriate
therapy, including treatment with no surgery. Currently,
observation is still not recommended for clinical com-
plete responders. This affirmation is supported by the ret-
rospective analysis of 488 patients with rectal cancer from
the Memorial Sloan-Kettering Cancer Center treated with
preoperative radiochemtoherapy. The clinical complete
response rate was 19% and of these, pathologic complete
response was observed in only 25%, showing that a signif-
icant percentage of clinical complete responders had per-
sistent deep tumors or nodal involvement. The authors
concluded that all patients with rectal cancer should
undergo resection, regardless of their response to preoper-
ative therapy [65]. Furthermore, locoregional tumor con-
trol should not be jeopardized by the justification of
quality of life (QOL). Two recent analyses about QOL
among patients with rectal cancer treated by preoperative
radiotherapy showed that the presence of a permanent
stoma did not affect the QOL outcome, when compared
with patients treated with sphincter-sparing surgery
[66,67].
Table 4: Death risk according to the main prognostic factors by Cox multivariate regression analysis.
Variable Category HR* [95% Conf. Interv.] HR§ [95% Conf. Interv.]
Tumor fixation Semi-fixed 1.0 Reference 1.0 Reference
Fixed 3.87 (2.1 – 7.0) 2.64 (1.2 – 5.7)
Postoperative N0 1.0 Reference 1.0 Reference
N stage N1/N2 2.51 (1.3 – 4.9) 2.13 (1.0 – 4.4)
* Crude harzard risk
§ Adjusted harzard risk for age (median of 61 years)Radiation Oncology 2006, 1:5 http://www.ro-journal.com/content/1/1/5
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In our study, the main adverse prognostic factors were fix-
ation of the primary tumor and the presence of lymph-
node metastasis (Table 3 and figure 2). Postoperative
TNM stage was a prognostic indicator for disease-free sur-
vival and local control but not for overall survival (Table
3). These findings reflect the influence of tumor extension
at the time of diagnosis, which can lead to distant dissem-
ination, the main cause of death among our patients.
Other series from literature also describe the postopera-
tive TNM staging as a strong prognostic factor, especially
if pelvic lymph-nodes are involved [42,44,68,69]. Clinical
response did not influence the results. This lack of influ-
ence was probably due to the small number of patients
who achieved clinical complete response. In the literature,
some series show no correlation between tumor response
to preoperative treatment and outcome [69-71], but most
series suggest that there is improved outcome with
increasing response to preoperative therapy [65,68,72-
77]. In our series, better actuarial 5-year local control was
observed among patients with primary tumor more than
6 cm from the anal verge (Table 3). The results of the
Dutch CKVO 95-04 trial, which compared RT followed by
surgery with only surgery, also showed better local control
among patients with primary tumors located more than 5
cm from the anal verge [9]. The reason for better local con-
trol in patients with higher located tumors is probably
related to the anatomic characteristics which facilitate
tumor resection with wider margins. Surgical technique
for tumor resection did not influence our results. Presum-
ably, absence of a difference, including local control, is
due to the fact that all patients treated with surgical resec-
tion had negative margins. Type of resection also did not
influence local recurrence among the 1748 patients of the
Dutch trial [9].
In our study, the acute toxicity observed was noticeable,
however similar to that reported in literature. In general,
the incidence of grade 3 acute toxicity during combined
modality treatment ranges about 15–25% [1]. Care must
be taken when CT is associated to RT during the preoper-
ative therapy, mainly because of leucopenia that can lead
patients to severe infections, septicemia and death.
Whether preoperative radiochemotherapy is more toxic
than only preoperative radiotherapy is an issue being
addressed in the ongoing randomized EORTC trial 22921.
Its preliminary results showed a greater incidence of grade
2 diarrhea in the CT group (34.3% Vs 17.3%; p < 0.005)
and two patients died preoperatively from toxicity in the
CT group [78]. To lessen the incidence of acute toxicity
when combined radiochemotherapy is needed for pelvic
Actuarial local control probability by tumor distance from  the anal verge Figure 5
Actuarial local control probability by tumor distance from 
the anal verge.
0 30 60 90
Months
120 150
P=0.0429
> 6 cm
d 6 cm
1.00
0.75
0.50
0.25
0.00
Actuarial overall survival probability by postoperative lymph- nodes stage Figure 3
Actuarial overall survival probability by postoperative lymph-
nodes stage.
0 30 60 90 120 150
P=0.0057
N1/N2
N0
1.00
0.75
0.50
0.25
0.00
Months
Actuarial disease-free survival probability by postoperative  TNM stage Figure 4
Actuarial disease-free survival probability by postoperative 
TNM stage.
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Months
120 150
P<0.0001
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tumors, intensity modulated radiation therapy (IMRT)
treatment planning has been tested, because it can reduce
the volume of irradiated small bowel and bone marrow
[79,80]. In the future, preoperative trials with new drugs
and radiotherapy with IMRT techniques will probably
reduce the incidence of acute toxicity, thereby increasing
the therapeutic ratio.
Conclusion
This retrospective analysis suggests that for locally
advanced rectal cancer, the preoperative combined radio-
chemotherapy strategy used was effective for local control.
Sphincter preservation for distal rectal tumors can com-
promise the local control. The main adverse prognostic
factors for survival and local control were fixation of the
primary tumor and presence of pelvic lymph-nodes
metastasis. Distant metastasis was the main pattern of fail-
ure, supporting the need of new drugs for adjuvant treat-
ment, mainly among patients with positive lymph-nodes.
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